Back to Browse Journals » Drug Design, Development and Therapy » Volume 5

Profile of ipilimumab and its role in the treatment of metastatic melanoma

Authors Patel SP, Woodman SE

Published Date December 2011 Volume 2011:5 Pages 489—495


Published 16 December 2011

Sapna P Patel, Scott E Woodman
Melanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abstract: Melanoma is an immunogenic cancer. However, the ability of the immune system to eradicate melanoma tumors is affected by intrinsic negative regulatory mechanisms. Multiple immune-modulatory therapies are currently being developed to optimize the immune response to melanoma tumors. Two recent Phase III studies using the monoclonal antibody ipilimumab, which targets the cytotoxic T-lymphocyte antigen (CTLA-4), a negative regulator of T-cell activation, have demonstrated improvement in overall survival of metastatic melanoma patients. This review highlights the clinical trial data that supports the efficacy of ipilimumab, the immune-related response criteria used to evaluate clinical response, and side-effect profile associated with ipilimumab treatment.

Keywords: ipilimumab, melanoma, T-cells, CTLA-4

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Osteoporosis – a current view of pharmacological prevention and treatment

Das S, Crockett JC

Drug Design, Development and Therapy 2013, 7:435-448

Published Date: 31 May 2013

Penetrating eye injuries from writing instruments

Kelly SP, Reeves GMB

Clinical Ophthalmology 2012, 6:41-44

Published Date: 30 December 2011

Treatment for primary hypothyroidism: current approaches and future possibilities

Chakera AJ, Pearce SHS, Vaidya B

Drug Design, Development and Therapy 2012, 6:1-11

Published Date: 22 December 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Surface activity of surfactant spiked with vitamin A

Vadim Bronshtein, Vugranam Venkatesh, Jas Aulakh, Philippe Chessex

Drug Design, Development and Therapy 2008, 2:145-150

Published Date: 14 August 2008

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008